Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

445 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Biodegradable polyanhydride-based nanomedicines for blood to brain drug delivery.
Brenza TM, Schlichtmann BW, Bhargavan B, Vela Ramirez JE, Nelson RD, Panthani MG, McMillan JM, Kalyanaraman B, Gendelman HE, Anantharam V, Kanthasamy AG, Mallapragada SK, Narasimhan B, Kanmogne GD. Brenza TM, et al. Among authors: kalyanaraman b. J Biomed Mater Res A. 2018 Nov;106(11):2881-2890. doi: 10.1002/jbm.a.36477. Epub 2018 Oct 26. J Biomed Mater Res A. 2018. PMID: 30369055 Free PMC article.
Neuroprotection by a mitochondria-targeted drug in a Parkinson's disease model.
Ghosh A, Chandran K, Kalivendi SV, Joseph J, Antholine WE, Hillard CJ, Kanthasamy A, Kanthasamy A, Kalyanaraman B. Ghosh A, et al. Among authors: kalyanaraman b. Free Radic Biol Med. 2010 Dec 1;49(11):1674-84. doi: 10.1016/j.freeradbiomed.2010.08.028. Epub 2010 Sep 7. Free Radic Biol Med. 2010. PMID: 20828611 Free PMC article.
A novel mitochondrially-targeted apocynin derivative prevents hyposmia and loss of motor function in the leucine-rich repeat kinase 2 (LRRK2(R1441G)) transgenic mouse model of Parkinson's disease.
Dranka BP, Gifford A, McAllister D, Zielonka J, Joseph J, O'Hara CL, Stucky CL, Kanthasamy AG, Kalyanaraman B. Dranka BP, et al. Among authors: kalyanaraman b. Neurosci Lett. 2014 Nov 7;583:159-64. doi: 10.1016/j.neulet.2014.09.042. Epub 2014 Sep 26. Neurosci Lett. 2014. PMID: 25263790 Free PMC article.
Mitoapocynin Treatment Protects Against Neuroinflammation and Dopaminergic Neurodegeneration in a Preclinical Animal Model of Parkinson's Disease.
Ghosh A, Langley MR, Harischandra DS, Neal ML, Jin H, Anantharam V, Joseph J, Brenza T, Narasimhan B, Kanthasamy A, Kalyanaraman B, Kanthasamy AG. Ghosh A, et al. Among authors: kalyanaraman b. J Neuroimmune Pharmacol. 2016 Jun;11(2):259-78. doi: 10.1007/s11481-016-9650-4. Epub 2016 Feb 2. J Neuroimmune Pharmacol. 2016. PMID: 26838361 Free PMC article.
Mito-Apocynin Prevents Mitochondrial Dysfunction, Microglial Activation, Oxidative Damage, and Progressive Neurodegeneration in MitoPark Transgenic Mice.
Langley M, Ghosh A, Charli A, Sarkar S, Ay M, Luo J, Zielonka J, Brenza T, Bennett B, Jin H, Ghaisas S, Schlichtmann B, Kim D, Anantharam V, Kanthasamy A, Narasimhan B, Kalyanaraman B, Kanthasamy AG. Langley M, et al. Among authors: kalyanaraman b. Antioxid Redox Signal. 2017 Nov 10;27(14):1048-1066. doi: 10.1089/ars.2016.6905. Epub 2017 Apr 4. Antioxid Redox Signal. 2017. PMID: 28375739 Free PMC article.
445 results